You are here

TapImmune

The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings

Yahoo/Benzinga

Sun, 07/14/19 - 04:09 pm

Seattle Genetics

Intuitive Surgical

Mirum Pharmaceuticals

Fulcrum Therapeutics

TapImmune and Marker Therapeutics merge to create new I/O company

Biopharma Dive

Tue, 05/15/18 - 11:41 am

Marker Therapeutics

immuno-oncology

TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

Yahoo

Thu, 04/21/16 - 03:14 pm

clinical trials

TapImmune: The Company Has Come A Long Way In One Year

Seeking Alpha

Tue, 01/5/16 - 11:16 am

Department of Defense

TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients

Yahoo

Tue, 06/23/15 - 10:53 am

HER2+ breast cancer

Three Companies with the Ingredients to Follow in the Footsteps of Advaxis

Yahoo

Tue, 06/16/15 - 06:52 pm

Propanc Health Group

PositiveID Corp

TapImmune Receives $1,000,000 from Strategic Investor

Yahoo

Tue, 03/10/15 - 10:16 am

TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials

Yahoo

Tue, 02/10/15 - 10:04 am

TapImmune offering would help take cancer vaccines to next clinical trials

Bizjournals.com

Tue, 01/13/15 - 08:55 am

TapImmune Releases Interim Data on Phase 1 Cancer Trial

Drug Discovery and Development

Wed, 09/17/14 - 08:42 am

TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens

Yahoo

Thu, 08/7/14 - 09:32 am

clinical trials

folate receptor alpha peptide vaccine

Tapimmune Announces Development of Advanced Immunotherapeutic Vaccine Expression and Delivery System

Yahoo

Wed, 10/9/13 - 11:26 am

immunotherapeutic vaccine expression

Phase I trial of novel HER2/neu Antigens will Start at Mayo; Isis Initiates Phase 2 Study of ISIS-APOCIIIRx

BioMedReports

Sat, 05/5/12 - 04:31 pm

HER-2/neu vaccine

Isis Pharmaceuticals

hypertriglyceridemia